Citi analyst Samantha Semenkow notes that Argenx (ARGX) shares were weak yesterday following Vyvgart Hytrulo’s inclusion in the FDA’s latest FAERS quarterly update, but would caution investors against over-interpreting the update since the FAERS database in general lacks important details. Argenx is currently running a Phase 4 switching study to better inform how best to transition patients from IVIg to Vyvgart Hytrulo, noted the firm, which views yesterday’s concerns as “overblown” and remains a buyers on weakness. Citi has a Buy rating and $803 price target on Argenx shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se’s Advancements in Neuromuscular Treatment Pipeline Drive Buy Rating
- Argenx selloff overblown, says Wells Fargo
- Argenx Se: Buy Rating Amidst Volatility and Proactive Risk Management
- Argenx weakness presents ‘attractive opportunity,’ says BofA
- FDA flags possible safety signals in new report, says RBC Capital